Identifying the profile of optimal candidates for antipsychotic depot therapy. A cluster analysis

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 8, 2008, Pages 1987-1993

  Heres, Stephan ^a   Hamann, Johannes ^a   Mendel, Rosmarie ^a   Wickelmaier, Florian ^b   Pajonk, Frank Gerald ^c   Leucht, Stefan ^a   Kissling, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Dr K Fontheim's Hospital for Mental Health   (Germany)

Author keywords

Antipsychotic; Depot; Psychopharmacology; Psychosis; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLUSTER ANALYSIS; DISEASE EXACERBATION; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; PRESCRIPTION; PSYCHIATRIST; RELAPSE; SCHIZOPHRENIA; TREATMENT REFUSAL;

ADULT; ANTIPSYCHOTIC AGENTS; CLUSTER ANALYSIS; DRUG PRESCRIPTIONS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT REFUSAL;

EID: 56449130841     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.09.025     Document Type: Article

References (33)

1. Ahn J., McCombs J.S., Jung C., Croudace T.J., McDonnell D., scher-Svanum H., et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 11 (2008) 48-56
2. an der Heiden W., and Hafner H. The epidemiology of onset and course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 250 (2000) 292-303
3. Byerly M., Fischer R., and Rush A. A comparison of clinician vs. electronic monitoring of antipsychotic adherence in schizophrenia [poster]. Presented at the 41st annual meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico (2002)
4. Chue P., Llorca P.M., Duchesne I., Leal A., Rosillon D., and Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 5 (2005) 266-274
5. Correll C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161 (2004) 414-425
6. Davis J.M., Matalon L., Watanabe M.D., Blake L., and Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 47 (1994) 741-773
7. Emsley R., Medori R., Koen L., Oosthuizen P.P., Niehaus D.J., and Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 28 (2008) 210-213
8. Goldberg R.W., Green-Paden L.D., Lehman A.F., and Gold J.M. Correlates of insight in serious mental illness. J Nerv Ment Dis 189 (2001) 137-145
9. Green A.I., Lieberman J.A., Hamer R.M., Glick I.D., Gur R.E., Kahn R.S., et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 86 (2006) 234-243
10. Gupta S., Hendricks S., Kenkel A.M., Bhatia S.C., and Haffke E.A. Relapse in schizophrenia: is there a relationship to substance abuse?. Schizophr. Res. 20 (1996) 153-156
11. Hamann J., Kolbe G., Cohen R., Leucht S., and Kissling W. How do psychiatrists choose among different antipsychotics?. Eur J Clin Pharmacol 61 (2005) 851-854
12. Heres S., Hamann J., Kissling W., and Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67 (2006) 1948-1953
13. Heres S., Schmitz F.S., Leucht S., and Pajonk F.G. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 22 (2007) 275-282
14. Jäger M., Riedel M., Messer T., Laux G., Pfeiffer H., Naber D., Schmidt LG., Gaebel W., Huff W., Heuser I., Kühn KU., Lemke MR., Rüther E., Buchkremer G., Gastpar M., Bottlender R., Strauss A., and Möller HJ. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 257 1 (2007) 47-53
15. Kamali M., Kelly B.D., Clarke M., Browne S., Gervin M., Kinsella A., et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry 21 (2006) 29-33
16. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 (2004) 1-56
17. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160 (2003) 1209-1222
18. McEvoy J.P., Johnson J., Perkins D., Lieberman J.A., Hamer R.M., Keefe R.S., et al. Insight in first-episode psychosis. Psychol Med 36 (2006) 1385-1393
19. Medori R., Wapenaar R., de Rosario A., Rouillon F., Gaebel W., Cordes J., et al. Relapse prevention and effectiveness in schizophrenia with risperidone long-acting injectable (RLAI) versus quetiapine. Poster presented at the 116th annual convention of the APA, Boston (2008)
20. Moller H.J., Llorca P.M., Sacchetti E., Martin S.D., Medori R., and Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20 (2005) 121-130
21. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115 (2007) 260-267
22. Patel M.X., and David A.S. Why aren't depot antipsychotics prescribed more often and what can be done about it?. Adv Psychiatr Treat 11 (2005) 203-213
23. Remington G., Kwon J., Collins A., Laporte D., Mann S., and Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 90 (2007) 229-237
24. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56 (1999) 241-247
25. Rubio G., Martinez I., Ponce G., Jimenez-Arriero M.A., Lopez-Munoz F., and Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51 (2006) 531-539
26. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 162 (2005) 947-953
27. Shi L., scher-Svanum H., Zhu B., Faries D., Montgomery W., and Marder S.R. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 58 (2007) 482-488
28. Sim K., Su A., Ungvari G.S., Fujii S., Yang S.Y., Chong M.Y., et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol 19 (2004) 103-109
29. Simpson G.M., Mahmoud R.A., Lasser R.A., Kujawa M., Bossie C.A., Turkoz I., et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 67 (2006) 1194-1203
30. Tiihonen J., Walhbeck K., Lonnqvist J., Klaukka T., Ioannidis J.P., Volavka J., et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333 (2006) 224
31. Weiden P.J., Kozma C., Grogg A., and Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55 (2004) 886-891
32. West J.C., Wilk J.E., Olfson M., Rae D.S., Marcus S., Narrow W.E., et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 56 (2005) 283-291
33. West J.C., Marcus S.C., Wilk J., Countis L.M., Regier D.A., and Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 34 5 (2008) 1001